Medtech endoscopy constant-currency sales growth measures endoscopy product revenue growth after removing foreign-currency translation effects.
Stryker reported 11.3% constant-currency growth in Endoscopy for the second quarter of 2026. Revenue was $1.004B, up from $899M a year earlier.
International growth outpaced the U.S.
Endoscopy revenue increased 10.2% in the United States and 16.5% in international markets on a constant-currency basis.
That split shows why a total business growth rate can mask meaningful geographic differences.
Constant-currency growth is not procedure volume
Endoscopy sales can move with shipment volume, product mix, capital-equipment demand, pricing, and geography.
Compare it with Instruments constant-currency sales growth and MedSurg and Neurotechnology operating margin.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsMedSurg and Neurotechnology product growth4 of 4 bridge concepts supportedContinue through this bridge:Instruments Constant-Currency GrowthMedical Constant-Currency GrowthVascular Constant-Currency Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare endoscopy growth
Compare endoscopy growth after foreign-exchange adjustment while keeping geographic mix and product demand distinct.
Explore more topics in the Financial Research Encyclopedia.